A cohort (N = 15) of patients affected by KS was also included in the AIDS Malignancy Consortium 095 Study, a multicentre phase I study, which tested nivolumab (anti-PD1) at 3 mg/kg every 2 weeks in PLWH with undetectable HIV-RNA and CD4 count of at least 100 cells/μL affected by solid tumours or KS. This evidence concerns the gene CD4 and Kaposi's sarcoma.